Brain Atrophy and White Matter Changes Grading Agreement on NCCT and MRI in Ischemic Stroke

William Betzner1, Nishita Singh2, Ibrahim Alhabli3

  • 1Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada. william.betzner@ucalgary.ca.

Clinical Neuroradiology
|February 27, 2026
PubMed
Abstract

Insights

Computed tomography (CT) scans show substantial agreement with MRI for assessing brain atrophy and white matter changes (WMC). Both imaging methods effectively predict 90-day stroke outcomes, suggesting CT is a viable tool in stroke research and practice.

Area of Science:

  • Neurology
  • Radiology
  • Stroke Medicine

Background:

  • Brain frailty measures, including atrophy and white matter changes (WMC), are crucial for predicting stroke outcomes.
  • Magnetic resonance imaging (MRI) is traditionally considered superior for visualizing these changes compared to computed tomography (CT).

Purpose of the Study:

  • To assess the agreement between baseline CT and follow-up MRI for brain atrophy and WMC.
  • To compare the discriminative ability of CT versus MRI in predicting 90-day functional outcomes after acute ischemic stroke.

Main Methods:

  • Observational analysis of CT and MRI data from the Alteplase compared to Tenecteplase (AcT) trial.
  • Expert visual rating of brain atrophy and WMC using established scales.
  • Gwet's agreement coefficient (AC1) for binary and full score agreement.
  • Logistic regression and DeLong's test for comparing discriminative ability (90-day mRS 0-1).

Main Results:

  • Substantial to almost-perfect agreement (AC1: 0.68-0.97) between CT and MRI for brain atrophy and WMC ratings.
  • No significant difference in the ability of CT versus MRI to discriminate 90-day functional outcomes (mRS 0-1).

Conclusions:

  • Expert CT ratings of brain atrophy and WMC demonstrate high agreement with MRI findings.
  • CT and MRI show comparable efficacy in predicting 90-day functional outcomes in acute ischemic stroke.
  • CT is a reasonable tool for evaluating brain frailty in clinical practice and stroke trials.